Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer Cuts Jobs, GSK Invests In Montreal
by Lisa M. Jarvis
November 5, 2012
| A version of this story appeared in
Volume 90, Issue 45
Pfizer is shedding some 300 jobs, primarily in sales and marketing, across Canada. Pfizer’s Canadian headquarters in a suburb of Montreal will bear the brunt of the layoffs, adding to earlier cutbacks in the region by Boehringer Ingelheim, AstraZeneca, Johnson & Johnson, and Merck & Co. In positive news for the region, Thrasos Therapeutics has secured $35 million in a new round of financing led by GlaxoSmithKline’s venture capital arm, SR One. The funds will be used to support the development of THR-184, a small molecule for the treatment of acute kidney injury.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter